BYSANTI (Milsaperidone) Patent Expiration, LOE Window & CMS Spending

BYSANTI (Milsaperidone) by Vanda: FDA Orange Book LOE 2044-05-31, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVanda
FDA Application & PathwayN220358 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2044-05-31
Orange Book Patents (*PED Extensions)140 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel